Pneumococcal conjugate second or third-dose vaccines (PCVc) in Latvia
Latvia: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 97.0% in 2025. ▲ Rising
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Latvia, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Latvia recorded 97.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
Compared with earlier readings it is up 5.4% on the previous year and up 14.1% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Latvia peaked at 97.0% in 2025 and was at its lowest, 0.0%, in 2008.
Latvia ranks 17th of 194 countries on this measure, in the top 10%.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Latvia, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 76.0% | — |
| 2012 | 55.0% | -27.6% |
| 2013 | 87.0% | +58.2% |
| 2014 | 84.0% | -3.4% |
| 2015 | 85.0% | +1.2% |
| 2016 | 84.0% | -1.2% |
| 2017 | 87.0% | +3.6% |
| 2018 | 84.0% | -3.4% |
| 2019 | 84.0% | +0.0% |
| 2020 | 91.0% | +8.3% |
| 2021 | 92.0% | +1.1% |
| 2022 | 87.0% | -5.4% |
| 2023 | 95.0% | +9.2% |
| 2024 | 92.0% | -3.2% |
| 2025 | 97.0% | +5.4% |
Latvia compared with similar countries
- Latvia's 97.0% is above the median for high income countries, which is 91.0%, 1.1× the median. (63 countries reporting)
- Latvia's 97.0% is above the median for Europe & Central Asia, which is 87.0%, 1.1× the median. (51 countries reporting)
Biggest year-on-year movements
Years where Pneumococcal conjugate second or third-dose vaccines (PCVc) in Latvia changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2013 | +58.2% | 55.0% | 87.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 72.6% | 0.0% | 87.0% | 10 |
| 2020s | 92.3% | 87.0% | 97.0% | 6 |
Countries ranked near Latvia
More health data for Latvia
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.3876 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,593 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -6.17 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0202 units per person (2025)
- Population ages 00-04, male, annual growth rate -6.02 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Latvia?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Latvia was 97.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Latvia?
- The highest recorded value was 97.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Latvia?
- The lowest recorded value was 0.0% in 2008.
- How does Latvia rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Latvia ranks 17th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Latvia?
- Over the last ten years it is up 14.1%. The long-run trend across the full record is rising.
- Where does this Latvia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).